PatternsRadar
Sign in

AMRUTANJANAmrutanjan Health Care Limited

NSE
Full chart
523.70INR+5.60 (+1.08%)Close · 6 Oct 2026
11 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹1,514 CrMarket cap
28.1P/E (TTM)
58.9%Delivery

Filings & corporate actions

66 results filed
CSV
Next results · Q2 FY27
Expected 5 Nov 2026 – 12 Nov 2026
Estimate: filed 36–43 days after quarter end, last 5 times
Dividend
₹2.90 per share · last 11 Sept 2026
2026
  • 11 SeptdividendDividend · ₹2.90 per share-0.5%
  • 11 AugresultsResults · Q1 FY27 · standalone-8.5%NSE
  • 14 JulshareholdingShareholding · 30 Jun 2026-0.8%NSE
  • 8 MayresultsResults · Q4 FY26 · standalone-0.5%NSE
  • 13 AprshareholdingShareholding · 31 Mar 2026-2.1%NSE
  • 6 FebdividendDividend · ₹1.00 per share+0.7%
  • 3 FebresultsResults · Q3 FY26 · standalone+9.0%NSE
  • 19 JanshareholdingShareholding · 31 Dec 20250.0%NSE

Reaction to results · all yearsrose on day 0 in 26 of 67 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2711 Aug 2026-8.5%-6.5%-5.6%14.6×
Q4 FY268 May 2026-0.5%+1.7%+2.3%0.8×
Q3 FY263 Feb 2026+9.0%+11.3%-2.1%3.2×
Q2 FY2610 Nov 2025+2.6%+0.2%-6.0%2.3×
Q1 FY2612 Aug 2025+2.2%+6.1%+12.8%1.8×
Q4 FY2515 May 2025-1.9%+0.2%-3.0%3.4×
Q3 FY2512 Feb 2025+2.1%-3.9%-5.1%1.4×
Q2 FY2512 Nov 2024+2.8%+5.0%+12.6%7.5×
Q1 FY2513 Aug 2024-2.8%+0.4%+3.9%6.2×
Q4 FY2424 May 2024-4.1%-6.1%+2.6%0.9×
Q3 FY249 Feb 2024+7.8%+11.0%+8.5%47.3×
Q2 FY2411 Nov 2023-0.2%+1.3%-2.1%1.2×
Q1 FY242 Aug 2023-1.1%-2.8%-5.8%0.8×
Q4 FY2331 May 2023+0.4%-3.4%+21.5%0.8×
Q3 FY2314 Feb 2023-7.8%-12.5%-14.5%5.7×
Q2 FY235 Nov 2022-1.4%-1.7%-5.8%1.5×
Q1 FY2312 Aug 2022-9.7%-12.0%-11.1%13.2×
Q4 FY2225 May 2022-1.5%+5.7%-1.0%1.2×
Q3 FY2211 Feb 2022+0.6%-5.0%-0.9%1.7×
Q2 FY229 Nov 2021-4.2%-2.8%-4.7%1.0×
Q1 FY2214 Aug 2021+4.8%+2.6%+9.2%2.7×
Q4 FY2127 May 2021-7.9%-7.2%-11.1%3.6×
Q3 FY2111 Feb 2021+1.2%+8.0%+1.8%7.7×
Q2 FY2112 Nov 2020+11.7%+16.0%+17.6%21.9×
Q1 FY2113 Aug 2020+0.8%-2.9%-13.7%3.4×
Q4 FY2018 Jun 2020-5.5%-6.2%-1.0%1.1×
Q3 FY2012 Feb 2020-3.3%-1.6%-36.7%3.3×
Q2 FY208 Nov 2019+4.3%-9.0%-7.5%1.2×
Q1 FY2013 Aug 2019+2.5%+0.7%+12.9%1.0×
Q4 FY1924 Jun 2019+3.3%+1.7%+0.9%1.8×
Q3 FY1919 Feb 2019+3.6%+2.8%+13.3%0.4×
Q2 FY1922 Nov 2018-0.3%+2.4%+14.4%0.2×
Q1 FY1924 Aug 2018+16.6%+4.9%-12.6%39.7×
Q4 FY1828 May 2018-0.1%-9.2%-0.5%1.1×
Q3 FY1816 Mar 2018+0.4%-2.5%+7.0%0.6×
Q2 FY1813 Nov 2017-2.6%-1.7%-3.7%2.5×
Q1 FY181 Sept 2017+0.1%+1.8%-6.9%1.2×
Q4 FY175 Jun 2017-0.8%+1.0%-0.9%0.3×
Q3 FY1710 Feb 2017-2.0%-6.3%-9.6%0.7×
Q2 FY1714 Nov 2016-5.2%-2.6%+5.3%0.2×
Q1 FY1722 Sept 2016+1.5%+0.7%+43.9%1.8×
Q4 FY1616 May 2016-0.7%-2.8%-2.6%0.6×
Q3 FY1613 Feb 2016+5.7%+3.6%+6.8%1.0×
Q2 FY167 Nov 2015-3.0%-4.1%-4.7%0.8×
Q1 FY1616 Aug 2015-0.2%-11.2%-10.3%0.2×
Q4 FY1520 May 2015+0.7%+1.0%-6.5%0.8×
Q3 FY1510 Feb 2015-0.4%+5.7%+20.7%0.3×
Q2 FY1527 Oct 2014-0.8%-3.5%+47.1%1.1×
Q1 FY1512 Aug 2014-6.5%+5.9%+53.7%1.3×
Q4 FY1430 May 2014+1.4%+18.2%+11.7%0.7×
Q3 FY147 Feb 2014-1.2%-5.4%-5.4%0.9×
Q2 FY1414 Nov 2013-1.4%-3.3%0.0%1.0×
Q1 FY147 Aug 2013-1.1%-1.9%-1.7%1.6×
Q4 FY131 Jun 2013-0.9%-1.7%-4.7%0.2×
Q3 FY1311 Feb 2013-1.2%-5.0%-11.0%0.6×
Q2 FY139 Nov 2012+1.0%-4.6%+1.2%0.4×
Q1 FY136 Aug 2012-2.0%-2.5%-4.2%1.0×
Q4 FY1230 May 2012-0.7%-0.6%+0.7%0.6×
Q3 FY1213 Feb 2012-2.5%-2.0%-7.0%0.4×
Q1 FY128 Aug 2011-2.0%-6.3%+0.7%0.5×
Q4 FY1128 May 2011-0.1%-0.1%-0.1%0.1×
Q3 FY1110 Feb 2011+3.8%+8.0%+15.0%0.9×
Q2 FY1115 Nov 2010-2.3%-7.6%-1.9%0.4×
Q1 FY119 Aug 2010-1.3%-3.3%-2.7%0.8×
Q4 FY1013 May 2010-4.4%-15.3%+6.2%0.2×
Q3 FY1030 Jan 2010+2.3%-1.2%+8.0%0.4×
Q2 FY104 Nov 2009————
Average-0.2%-0.9%+1.9%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+9.5%
Profit YoY-47.5%
Interest cost YoY—
Revenue QoQ-31.2%
Profit QoQ-73.0%
CAGR2Y3Y4Y5Y6Y7Y
Revenue——————
Profit——————

Key data

CSV
Open527.00
Day range516.00 – 527.00
52-week range476.50 – 760.15
From 52w high-31.1%
RSI (14)63.4
ATR (14)14.39
Volume27.7K
Avg volume (20D)44.4K
Rel volume0.62×
Volatility (1Y)27.6%
Turnover₹1.5Cr
SMA 50 / 200508.67 / 559.13

Delivery percentage

Latest · 6 Oct 202658.9%
20-day avg57.2%
1-year avg58.9%
Percentile (own history)73rd
Range8.7–95.1%
Sessions1,731

Over the last 20 sessions AMRUTANJAN settled 57.2% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 58.9%. The latest session ranks higher than 73% of the 1,731 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+1.08%+3.39%+3.22%-2.67%+2.56%-27.80%

Valuation

CSV
Market cap₹1,514 Cr
P/E (TTM)28.1
EPS (TTM)18.67
Shares outstanding2.89Cr
Listed2 Jan 2015

Ownership

CSV
Promoter46.52%
Promoter Δ QoQ0.00 pp
Public53.45%
FII2.44%
DII12.28%
Pledged0.00%

Quarterly results · standalone

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)117.7141.0149.8103.0
YoY chg——+10.6%+9.5%
Net profit (₹ Cr)14.019.516.24.4
YoY chg——+6.7%-47.5%
Net margin11.9%13.8%10.8%4.2%
EPS4.836.735.601.51

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 46.52% · public 53.45%
30 Sept 2021: promoter 50.02%31 Dec 2021: promoter 50.02%31 Mar 2022: promoter 50.02%30 Jun 2022: promoter 50.02%30 Sept 2022: promoter 50.02%31 Dec 2022: promoter 50.02%31 Mar 2023: promoter 50.04%30 Jun 2023: promoter 50.04%30 Sept 2023: promoter 50.59%31 Dec 2023: promoter 50.59%31 Mar 2024: promoter 50.59%30 Jun 2024: promoter 50.59%30 Sept 2024: promoter 46.52%31 Dec 2024: promoter 46.52%31 Mar 2025: promoter 46.52%30 Jun 2025: promoter 46.52%30 Sept 2025: promoter 46.52%31 Dec 2025: promoter 46.52%31 Mar 2026: promoter 46.52%30 Jun 2026: promoter 46.52%
2021-092026-06
  • Promoter
  • Public and others
Promoter
46.52%
Public
53.45%
Promoter change
0.00 pp
Filed
14 Jul 2026
FII
2.44%
DII
12.28%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
Standalone
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations99.3117.0127.183.7109.9122.8135.494.0117.7141.0149.8103.0
Other income3.93.85.54.54.04.44.84.44.34.14.73.8
Total income103.3120.8132.688.2114.0127.1140.298.5122.0145.2154.5106.8
Total expenses94.197.1113.081.898.0101.1119.487.2102.8117.5125.998.7
└ Finance costs0.00.10.00.10.10.10.00.10.00.00.00.0
└ Depreciation1.61.61.51.61.71.71.61.51.61.61.61.9
Profit before tax9.223.719.66.315.926.020.911.319.226.421.06.1
Tax expense2.46.35.91.74.16.75.73.05.36.94.81.7
Net profit6.817.413.74.611.819.215.28.314.019.516.24.4
EPS2.366.054.721.604.086.665.252.874.836.735.601.51
Net margin6.90%14.91%10.75%5.51%10.73%15.68%11.21%8.84%11.86%13.79%10.81%4.24%
PBT margin9.27%20.26%15.43%7.58%14.50%21.17%15.40%12.01%16.33%18.69%14.03%5.89%
Tax rate25.60%26.39%30.33%27.30%26.00%25.95%27.22%26.40%27.34%26.22%22.95%28.07%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 11 Aug 2026.

AMRUTANJAN at a glance

  • AMRUTANJAN closed at ₹523.7 on 6 Oct 2026, +1.08% on the day, -27.8% over one year, 31.1% below its 52-week high of ₹760.15.
  • Delivery was 58.9% of traded quantity on 6 Oct 2026, the 73rd percentile of its own 1,731 sessions with a reading (20-session average 57.2%, 1-year average 58.9%).
  • Market capitalisation is ₹1,514 crore at a trailing P/E of 28.1 (trailing EPS ₹18.67).
  • Q1 FY27 results (standalone, filed 11 Aug 2026): revenue ₹103 crore (+9.5% year on year), net profit ₹4 crore (-47.5%); the price moved -8.5% on the first session after.
  • Promoters held 46.52% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 5 Nov 2026 and 12 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE098F01031
SeriesEQ
Listed2 Jan 2015
History from5 Nov 2009
Sessions4,193

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE